Dejan Juric
Advertisement
Articles by Dejan Juric
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib
ByEmily J. Gallagher,Heather Moore,Mario E. Lacouture, MD,Susan F. Dent,Azeez Farooki, MD,Marcus D. Goncalves,Claudine Isaacs, MD,Abigail Johnston,Dejan Juric,Zoe Quandt,Laura Spring,Brian Berman,Melanie Decker,Gabriel N. Hortobagyi, MD, FACP,Benjamin H. Kaffenberger,Bernice Y. Kwong,Timothy Pluard,Ruta Rao, MD,Lee Schwartzberg, MD, FACP,Michael S. Broder
Advertisement
Latest Updated Articles
![TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bb58c5f3c3692dc35c19320bb63c3df864f9b79b-1500x722.png?w=300&fit=crop&auto=format)
Advertisement
Advertisement
Trending on CancerNetwork
1
Radiotherapy Dose Escalation Did Not Improve Efficacy/QOL in Anal Cancer
2
FDA Receives BLA for Ivonescimab Combo in Advanced/Metastatic EGFR+ NSCLC
3
FDA Issues New CRL for Tabelecleucel in Epstein Barr Virus–Positive PTLD
4
FDA Accepts NDA For Pimicotinib in Tenosynovial Giant Cell Tumors
5